Literature DB >> 35066691

Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells.

Xialin Chen1,2, Rong Ji3, Jianjiang Liu2, Xueying Jin2, Hong Zhu4, Jianfang Wang5, Ming Chen6,7.   

Abstract

BACKGROUND: Previous reports stated that DNA polymerase ζ is highly expressed in lung cancer tissues. The present study aimed to investigate the roles and underlying mechanism of DNA polymerase ζ in lung cancer cell radioresistance.
METHODS: The A549 and HCC827 cells were used to evaluate the effects of different doses of radiation on the mRNA and protein expressions of DNA polymerase ζ. Multiple assays, including PCR, western blot, flow cytometry, and EdU have been used to investigate the roles of DNA polymerase ζ on the cellular behaviors of A549 and HCC827 cells.
RESULTS: The mRNA and protein expression of REV7L in A549 and HCC827 cells were significantly increased after 6 Gy irradiation compared to the control group. In A549 and HCC827 cells, over-expression of polymerase ζ decreased the radiosensitivity, inhibited cell apoptosis as well as reduced oxidative stress; while the knockdown of polymerase ζ showed the opposite effects. Knockdown of Polymerase ζ in xenograft animal models significantly decreased tumor size and induced oxidative stress of tumor tissues after irradiation. DISCUSSION: Our results provided a theoretical basis for targeting DNA polymerase ζ to improve the radiosensitivity of the lung cancer cells to radiotherapy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  DNA polymerase; Lung cancer; Oxidative stress; Radioresistance

Mesh:

Substances:

Year:  2022        PMID: 35066691     DOI: 10.1007/s00280-021-04360-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  1 in total

1.  MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.

Authors:  Xialin Chen; Hong Zhu; Wanli Ye; Yayun Cui; Ming Chen
Journal:  Mol Med Rep       Date:  2018-12-04       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.